Evaluation of Galcanezumab for the Prevention of Episodic Migraine: The EVOLVE-1 Randomized Clinical Trial.

ABSTRACT:

Importance

Migraine is a disabling neurological disease characterized by severe headache attacks. Treatment options reduce migraine frequency for many patients, but adverse effects lead to discontinuation in many patients.

Objective

To demonstrate that galcanezumab is superior to placebo in the prevention of episodic migraine with or without aura.

Design, setting, and participants

The EVOLVE-1 (Evaluation of LY2951742 in the Prevention of Episodic Migraine 1) trial was a double-blind, randomized, placebo-controlled (January 11, 2016, to March 22, 2017) trial comparing galcanezumab (120 mg and 240 mg) vs placebo. Patients received treatments once monthly for 6 months (subcutaneous injection via prefilled syringe) and were followed up for 5 months after their last injec

SUBMITTER: Stauffer VL 

PROVIDER: S-EPMC6143119 | biostudies-literature | 2018 Sep

REPOSITORIES: biostudies-literature